FeedingTrends
Pd-1 and Pdl-1 Inhibitors Market 2023-2029
4 months ago
4 min read

Pd-1 and Pdl-1 Inhibitors Market 2023-2029

The global PD-1 and PDL-1 Inhibitors market was valued at US$ 40690 million in 2022 and is projected to reach US$ 64070 million by 2029, at a CAGR of 6.7% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

PD-1 inhibitors and PD-L1 inhibitors are a group of checkpoint inhibitors being developed for the treatment of cancer. PD-1 and PD-L1 are both proteins present on the surface of cells. Immune checkpoint inhibitors such as these are emerging as a front-line treatment for several types of cancer.

Report Sample includes: - Table of Contents - List of Tables & Figures - Charts - Research Methodology Get FREE Sample of this Report at https://www.24marketreports.com/report-sample/global-pd-pdl-inhibitors-forecast-2023-2029-93

This report aims to provide a comprehensive presentation of the global market for PD-1 and PDL-1 Inhibitors, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PD-1 and PDL-1 Inhibitors. This report contains market size and forecasts of PD-1 and PDL-1 Inhibitors in global, including the following market information:

Global PD-1 and PDL-1 Inhibitors Market Revenue, 2018-2023, 2024-2029, ($ millions)

Global PD-1 and PDL-1 Inhibitors Market Sales, 2018-2023, 2024-2029, (K Units)

Global top five PD-1 and PDL-1 Inhibitors companies in 2022 (%)

North America is the largest consumption place, with a consumption market share nearly 60.40% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 20.66%.Market competition is intense. Merck, Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical etc. are the leaders of the industry.

We surveyed the PD-1 and PDL-1 Inhibitors manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global PD-1 and PDL-1 Inhibitors Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)

Global PD-1 and PDL-1 Inhibitors Market Segment Percentages, by Type, 2022 (%)

  • Pembrolizumab

  • Nivolumab

  • Atezolizumab

  • Durvalumab

  • Avelumab

Global PD-1 and PDL-1 Inhibitors Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)

Global PD-1 and PDL-1 Inhibitors Market Segment Percentages, by Application, 2022 (%)

  • Stomach Cancer

  • Liver Cancer

  • Kidney Ccancer

  • Bladder Cancer

  • Cervical Cancer

  • Other

Global PD-1 and PDL-1 Inhibitors Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)

Global PD-1 and PDL-1 Inhibitors Market Segment Percentages, By Region and Country, 2022 (%)

  • North America

  • US

  • Canada

  • Mexico

  • Europe

  • Germany

  • France

  • U.K.

  • Italy

  • Russia

  • Nordic Countries

  • Benelux

  • Rest of Europe

  • Asia

  • China

  • Japan

  • South Korea

  • Southeast Asia

  • India

  • Rest of Asia

  • South America

  • Brazil

  • Argentina

  • Rest of South America

  • Middle East & Africa

  • Turkey

  • Israel

  • Saudi Arabia

  • UAE

  • Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

  • Key companies PD-1 and PDL-1 Inhibitors revenues in global market, 2018-2023 (Estimated), ($ millions)

  • Key companies PD-1 and PDL-1 Inhibitors revenues share in global market, 2022 (%)

  • Key companies PD-1 and PDL-1 Inhibitors sales in global market, 2018-2023 (Estimated), (K Units)

  • Key companies PD-1 and PDL-1 Inhibitors sales share in global market, 2022 (%)

Further, the report presents profiles of competitors in the market, key players include:

  • GlaxoSmithKline plc

  • Bristol-Myers Squibb Company

  • Arcus Biosciences, Inc.

  • Agenus Inc

  • F. Hoffmann-La Roche Ltd

  • Astra Zeneca PLC

  • Beigene Ltd

  • Incyte Corporation

  • Biocad

  • CStone Pharmaceuticals

  • Shanghai Junshi Bioscience Co. Ltd

  • Shanghai Henlius Biotech, Inc.

  • Jiangsu HengRui Medicine Co., Ltd.

  • Lee's Pharmaceutical Limited

Outline of Major Chapters:

  • Chapter 1: Introduces the definition of PD-1 and PDL-1 Inhibitors, market overview.

  • Chapter 2: Global PD-1 and PDL-1 Inhibitors market size in revenue and volume.

  • Chapter 3: Detailed analysis of PD-1 and PDL-1 Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

  • Chapter 6: Sales of PD-1 and PDL-1 Inhibitors in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

  • Chapter 8: Global PD-1 and PDL-1 Inhibitors capacity by region & country.

  • Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

  • Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.

  • Chapter 11: The main points and conclusions of the report.

Get the Complete Report & TOC at https://www.24marketreports.com/life-sciences/global-pd-pdl-inhibitors-forecast-2023-2029-93

CONTACT US:276 5th Avenue, New York , NY 10001,United StatesInternational: (+1) 646 781 7170Follow Us On linkedin :-https://www.linkedin.com/company/24-market-reports

Appreciate the creator